Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study

Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study

Abstract Aims To compare 12‐month clinical effectiveness of insulin glargine 300 units/mL (Gla‐300) versus first‐generation basal insulin analogues (BIAs) (insulin glargine 100 units/mL [Gla‐100] or insulin detemir [IDet]) in patients with type 2 diabetes (T2D) who were at high risk of hypoglycaemia...

Full description

Bibliographic Details
Main Authors: Sean D. Sullivan, Nick Freemantle, Rishab A. Gupta, Jasmanda Wu, Charlie J. Nicholls, Jukka Westerbacka, Timothy S. Bailey
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
high risk
hypoglycaemia
Insulin glargine 300 units/mL
real‐world study
type 2 diabetes
Online Access:https://doi.org/10.1002/edm2.306

Internet

https://doi.org/10.1002/edm2.306

Similar Items